Rigel Pharmaceuticals, Inc. (RIGL) News

Rigel Pharmaceuticals, Inc. (RIGL): $3.90

0.07 (+1.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter RIGL News Items

RIGL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RIGL News Highlights

  • RIGL's 30 day story count now stands at 8.
  • Over the past 17 days, the trend for RIGL's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • CVAC, LUNG and MRNA are the most mentioned tickers in articles about RIGL.

Latest RIGL News From Around the Web

Below are the latest news stories about Rigel Pharmaceuticals Inc that investors may wish to consider to help them evaluate RIGL as an investment opportunity.

Rigel to Participate in Three Upcoming Investor Conferences

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following virtual investor conferences in September:

Yahoo | September 2, 2021

Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19, in Clinical Infectious Diseases, an official publication of the Infectious Disease Society of America. The study was sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), in collaboration with Inova Health System.

Yahoo | September 1, 2021

Why Did the FDA Reject Rigel's EUA Application for Its COVID-19 Therapy?

Rigel Pharmaceuticals (NASDAQ: RIGL) recently received a thumbs-down from the Food and Drug Administration for an EUA filing for its COVID therapeutic candidate. In this Motley Fool Live video recorded on Aug. 18, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why the FDA turned down an EUA for Rigel's experimental COVID therapy.

Yahoo | August 26, 2021

Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations

Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.

Yahoo | August 18, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGL

NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") (NASDAQ: RIGL). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The

PR Newswire | August 16, 2021

Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA

Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.

Yahoo | August 16, 2021

Rigel Stock Falls After Update From COVID-19 Program

The FDA has informed Rigel Pharmaceuticals Inc (NASDAQ: RIGL ) that data submitted in May from fostamatinib Phase 2 trial

Business Insider Markets | August 13, 2021

Rigel : FDA Didn''t Issue EUA For Fostamatinib For Treatment Of COVID-19 In Hospitalized Adults

(RTTNews) - Rigel Pharmaceuticals Inc. (RIGL) said Friday that the U.S. Food and Drug Administration did not issue emergency use authorization for fostamatinib for the treatment of COVID-19 in hospitalized adults, due to insufficient clinical data. In Friday pre-market trade, RIGL was trading at $3.60, down $0.53 or 12.83%. "The FDA has

Business Insider Markets | August 13, 2021

Rigel Pharmaceuticals Provides Update on COVID-19 Program

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that clinical data submitted in late-May from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib to treat hospitalized patients suffering from COVID-19 are insufficient for an emergency use authorization (EUA) at this time. The FDA noted in their response that they remain committed to working with Rigel in the development of fostamatinib for COVID-19 a

Yahoo | August 13, 2021

Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options

Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.

Yahoo | August 11, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6371 seconds.